Previous 10 | Next 10 |
Relapsed and refractory Ewing sarcoma patients to receive seclidemstat in combination with chemotherapy agents as second- and third-line therapy; Protocol amendment expands and improves access to addressable patient population Ewing-related sarcoma patients to receive single-age...
Comstock Mining (LODE) +285% after buying stake in lithium-ion battery recycler.TDH Holdings (PETZ) +248%.Dogness (International) (DOGZ) +110%.Oncolytics Biotech (ONCY) +54%.ZW Data Action Technologies (CNET) +42%.China Xiangtai Food (PLIN) +41%.AirNet Technology (ANTE) +34%.Aqua Metals ...
Salarius Pharmaceuticals (SLRX) has completed the dose-escalation stage and established the recommended Phase 2 dose (RP2D) for its Phase 1/2 trial in relapsed/refractory (R/R) Ewing sarcoma, a rare and deadly pediatric bone and soft tissue cancer. The primary objectives of the study were to ...
Seclidemstat safety profile affirmed; Recommended Phase 2 dose established Demonstrated preliminary evidence of seclidemstat drug activity in subset of Ewing-related sarcoma patients HOUSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc . (Nasdaq: SL...
Socket Mobile (SCKT) +181% after launching first enterprise-grade scanners for Apple iPhone 12 series.ALJ Regional Holdings (ALJJ) +71%.500.com Limited (WBAI) +74% after acquisition of crypto mining pool.Urban Tea, Inc. (MYT) +55%.Torchlight Energy Resources, Inc. (TRCH)...
HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, LLC , a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that it will participate in the BIO CEO & In...
Anchiano Therapeutics (ANCN) -28%.Pulmatrix (PULM) -21% on direct offering.United States Antimony (UAMY) -21% on direct offering.Cancer Genetics (CGIX) -21% on stock offering.BioHiTech Global (BHTG) -15%.Fluidigm (FLDM) -14% on Q4 earnings; inks distrib...
Salarius Pharmaceuticals (SLRX) has regained compliance with Nasdaq's minimum bid price requirement for continued listing.Last week, the company received second installment of $1.7M in payments from CPRIT.Shares up 3% premarket. For further details see: Salarius Pharmaceutical...
HOUSTON, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc . (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that it has received a letter fr...
HOUSTON, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharm aceuticals, Inc . (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that Daniela Y. Santiesteba...
News, Short Squeeze, Breakout and More Instantly...
Salarius Pharmaceuticals Inc. Company Name:
SLRX Stock Symbol:
NASDAQ Market:
Salarius Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.7% to $112.28 on volume of 455,296,152 shares Ford Motor Company (F) fell 18.4% to $11.16 on volume of 256,384,806 shares PROSHARES TRUST (SQQQ) rose 3.4% to $9.37 on volume of 246,885,889 shares Sel...
Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) is one of today's top gainers. The company's shares have moved 57.21% on the day to $3.37. Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Secli...
A look at the top 10 most actives in the United States Predictive Oncology Inc. (POAI) rose 115.9% to $2.3099 on volume of 63,737,015 shares Selina Hospitality PLC (SLNA) fell 11.2% to $0.0406 on volume of 59,708,638 shares NVIDIA Corporation (NVDA) fell 1.4% to $112.695 on volume of 52,2...